Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 3
2006 5
2007 3
2008 3
2010 4
2011 2
2012 5
2013 2
2014 2
2015 8
2016 9
2017 9
2018 10
2019 9
2020 23
2021 10
2022 11
2023 11
2024 10
2025 5
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

128 results

Results by year

Filters applied: . Clear all
Page 1
Nonmyeloablative conditioning combined with the anti-CD117 antibody briquilimab in older adults with high-risk AML and MDS.
Muffly L, Lee CJ, Gandhi A, Varma A, Scott BL, Patel SS, Shiraz P, Youn M, Yanagiba C, Arulprakasam J, Le A, Kwon HS, Long-Boyle J, Shizuru JA, Pang WW, Artz AS. Muffly L, et al. Among authors: scott bl. Blood. 2026 May 28;147(22):2610-2620. doi: 10.1182/blood.2025031858. Blood. 2026. PMID: 41785374 Clinical Trial.
Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor cells (HSPC) and myeloid malignant cells, we conducted a phase 1 trial examining briquilimab plus nonmyeloablative fludarabine (Flu) and total body irradiation (TBI) as conditioning for …
Based on preclinical data demonstrating the antibody clears hematopoietic stem and progenitor cells (HSPC) and myeloid malignant cells, we c …
PTCy or ATG for Matched Transplantation in Myelofibrosis.
Chiusolo P, Bacigalupo A, Salit R, Schroeder T, Finazzi MC, Gurnari C, Pagliuca S, Metzdorf J, Rautenberg C, Robin M, Rubio MT, Maciejewski J, Popat U, Rambaldi A, Reinhardt HC, Scott B, Kröger N, Gagelmann N. Chiusolo P, et al. Among authors: scott b. Am J Hematol. 2026 Jun;101(6):1192-1195. doi: 10.1002/ajh.70244. Epub 2026 Feb 23. Am J Hematol. 2026. PMID: 41728684 No abstract available.
Defining remission following hematopoietic cell transplant for myelofibrosis: an international expert panel consensus.
Salit RB, Hexner EO, Gagelmann N, Kröger N, McLornan DP, Jain T, Gupta V, Hobbs GS, Tamari R, Robin M, Scott B, Saber W. Salit RB, et al. Among authors: scott b. Leukemia. 2025 Dec;39(12):2862-2865. doi: 10.1038/s41375-025-02754-9. Epub 2025 Oct 13. Leukemia. 2025. PMID: 41083679 Free PMC article. Review.
Twelve MF experts from the United States, Canada, and Europe contributed by completing multiple choice and open-ended surveys as well as serial discussions by videoconference. ...
Twelve MF experts from the United States, Canada, and Europe contributed by completing multiple choice and open-ended surveys as well …
Advancing drug development in myelodysplastic syndromes.
Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji R, Sekeres MA, Scott B, Buckstein R, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic S, Norsworthy K. Mina A, et al. Among authors: scott b. Blood Adv. 2025 Mar 11;9(5):1095-1104. doi: 10.1182/bloodadvances.2024014865. Blood Adv. 2025. PMID: 39786387 Free PMC article. Review.
Role of molecular alterations in transplantation decisions for patients with primary myelofibrosis.
Luque Paz D, Gagelmann N, Benajiba L, Riou J, Salit R, Orvain C, Schroeder T, Bories C, Gurnari C, Badbaran A, Boyer F, Pagliuca S, Rautenberg C, Tavitian S, Pangiota V, Ianotto JC, Thol F, Cayssials E, Heuser M, Rubio MT, Cassinat B, Daltro de Oliveira R, Sauter C, Maciejewski JP, Reinhardt HC, Scott BL, Ugo V, Kröger N, Kiladjian JJ, Robin M. Luque Paz D, et al. Among authors: scott bl. Blood Adv. 2025 Feb 25;9(4):797-807. doi: 10.1182/bloodadvances.2024014368. Blood Adv. 2025. PMID: 39561372 Free PMC article.
Consistency of Spleen and Symptom Reduction Regardless of Cytopenia in Patients With Myelofibrosis Treated With Pacritinib.
Gagelmann N, Bose P, Gupta V, McLornan DP, Vachhani P, Al-Ali HK, Ali H, Treskes P, Buckley S, Roman-Torres K, Scott B. Gagelmann N, et al. Among authors: scott b. Clin Lymphoma Myeloma Leuk. 2024 Nov;24(11):796-803. doi: 10.1016/j.clml.2024.06.012. Epub 2024 Jul 2. Clin Lymphoma Myeloma Leuk. 2024. PMID: 39034203 Free article. Clinical Trial.
PATIENTS AND METHODS: In order to assess the impact of baseline blood counts on pacritinib efficacy, an analysis of efficacy outcomes by baseline platelet and hemoglobin levels was performed using data pooled from 2 Phase 3 studies of pacritinib in patients with MF (PERSIS …
PATIENTS AND METHODS: In order to assess the impact of baseline blood counts on pacritinib efficacy, an analysis of efficacy outcomes …
Pediatric Hematology and Oncology Patients on Extracorporeal Membrane Oxygenation: Outcomes in a Multicenter, Retrospective Cohort, 2009-2021.
Mowrer MC, Lima L, Nair R, Li X, Sandhu H, Bridges B, Barbaro RP, Bhar S, Nkwantabisa R, Ghafoor S, Reschke A, Olson T, Malone MP, Shah N, Zinter MS, Gehlbach J, Hollinger L, Scott BL, Lerner RK, Brogan TV, Raman L, Potera RM. Mowrer MC, et al. Among authors: scott bl. Pediatr Crit Care Med. 2024 Nov 1;25(11):1026-1034. doi: 10.1097/PCC.0000000000003584. Epub 2024 Jul 19. Pediatr Crit Care Med. 2024. PMID: 39028213
Donor types and outcomes of transplantation in myelofibrosis: a CIBMTR study.
Jain T, Estrada-Merly N, Salas MQ, Kim S, DeVos J, Chen M, Fang X, Kumar R, Andrade-Campos M, Elmariah H, Agrawal V, Aljurf M, Bacher U, Badar T, Badawy SM, Ballen K, Beitinjaneh A, Bhatt VR, Bredeson C, DeFilipp Z, Dholaria B, Farhadfar N, Farhan S, Gandhi AP, Ganguly S, Gergis U, Grunwald MR, Hamad N, Hamilton BK, Inamoto Y, Iqbal M, Jamy O, Juckett M, Kharfan-Dabaja MA, Krem MM, Lad DP, Liesveld J, Al Malki MM, Malone AK, Murthy HS, Ortí G, Patel SS, Pawarode A, Perales MA, van der Poel M, Ringden O, Rizzieri DA, Rovó A, Savani BN, Savoie ML, Seo S, Solh M, Ustun C, Verdonck LF, Wingard JR, Wirk B, Bejanyan N, Jones RJ, Nishihori T, Oran B, Nakamura R, Scott B, Saber W, Gupta V. Jain T, et al. Among authors: scott b. Blood Adv. 2024 Aug 27;8(16):4281-4293. doi: 10.1182/bloodadvances.2024013451. Blood Adv. 2024. PMID: 38916866 Free PMC article.
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for International Blood and Marrow Transplant Research registry data for HCTs done between 2013 and 2019. ...In study-eligible 1032 patients who …
We evaluate the impact of donor types on outcomes of hematopoietic cell transplantation (HCT) in myelofibrosis, using the Center for Interna …
128 results